Quoin Pharma QRX003 Shows Promising Netherton Syndrome Results
Quoin Pharmaceuticals announced further clinical evidence supporting the efficacy of QRX003, its topical treatment for Netherton Syndrome. Data from...
Quoin Pharmaceuticals announced further clinical evidence supporting the efficacy of QRX003, its topical treatment for Netherton Syndrome. Data from...
Exicure, Inc. acquired GPCR Therapeutics USA Inc. and entered into a licensing and collaboration agreement with GPCR Therapeutics Inc....
Segal Trials, a clinical research network specializing in psychiatric disorders, significantly contributed to the successful Phase 2 trial of...
ExThera Medical received funding from the Medical Technology Enterprise Consortium (MTEC) for a randomized controlled trial. The trial will...
Vaxxas, a clinical-stage biotech company, is developing a heat-stable, dried-formulation mRNA vaccine delivered via its microarray patch (HD-MAP) with...
OKYO Pharma, a clinical-stage biopharmaceutical company developing treatments for neuropathic corneal pain (NCP) and dry eye disease (DED), has...
Anthos Therapeutics announced the publication of positive results from its AZALEA-TIMI 71 study in the •New England Journal of...
Tiziana Life Sciences has discovered new immune biomarkers in patients with non-active secondary progressive multiple sclerosis (na-SPMS) treated with...
Cullgen Inc., a clinical-stage biopharmaceutical company, has initiated human trials for CG001419, a potential first-in-class, oral, pan-TRK protein degrader...
Lisata Therapeutics announced preliminary data from Cohort A of its Phase 2 ASCEND trial evaluating certepetide, combined with standard...